pembrolizumab,eftilagimod alpha
immutep,merck
['nsclc', 'tacti-002', 'sclc', 'immutep']
#asco2022 updates:
at the 2022, in an oral presentation, presented an encouraging overall response rate in the phase ii tacti-002 #clinicaltrial in the first-line #nsclc #treatment. click here to know more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry